ArticleBMC cancer2025
Global burden of respiratory system cancers in 2022 and 2050: incidence and mortality estimates from GLOBOCAN.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Lifetime risk of respiratory system cancers across 185 countries: Global variation, socioeconomic inequalities, and ecological associations with air pollution.Preventive medicine reports · 2026Article
- Design, Synthesis and Characterization of Anti-CTLA4 Peptide Conjugated Gemcitabine Prodrug Nanoparticles for Targeted Lung Cancer Chemoimmunotherapy.Pharmaceutical research · 2026Article
- The Treg-cell death axis in lung cancer: implications for immune evasion and novel therapeutic strategies.Molecular cancer · 2026Review
- Association between preoperative inflammatory biomarkers and postoperative pulmonary complications in stage I-II non-small cell lung cancer: a retrospective study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundRespiratory system cancers, primarily encompassing lung cancer, tracheal cancer, bronchial cancer, and laryngeal cancer, severely jeopardize patients’ lives. Therefore, this study aimed to investigate the global burden of respiratory system cancers in 2022 using the GLOBOCAN 2022 database, to inform global prevention strategies.
methodsThis study extracted data of respiratory system cancers from GLOBOCAN 2022, stratified into two subsets: laryngeal cancer (C32) and tracheal, bronchial, and lung cancers (C33, C34). It analyzed the incidence, mortality, and age-standardized rates (ASR) of both subsets across world regions, HDI levels, genders, and age groups, and projected their disease burden from 2022 to 2050.
resultsFor tracheal, bronchial, and lung cancers (C33, C34), Hungary had the highest age-standardized incidence rates (ASIR) and age-standardized mortality rates (ASMR). For laryngeal cancer alone (C32), India had the highest global ASIR and ASMR. Very high HDI regions had the highest ASR for the combined cancers. Males had higher incidence and mortality than females across regions and HDI strata for both subsets. Incidence and mortality rose markedly after age 40, with faster growth in males. Projection results indicated that by 2050, the male incidence and mortality rates of tracheal, bronchial, and lung cancers would increase by 87.97% and 94.75%, respectively. For laryngeal cancer, the number of male incident cases and male deaths was expected to grow by 72.53% and 81.33%, respectively.
conclusionThis study, grounded in the GLOBOCAN 2022 database, elucidated the respiratory system cancers (lung cancer, tracheal cancer, bronchial cancer, and laryngeal cancer) global burden. It thereby furnished theoretical references for subsequent preventive measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.